Stock listing
NASDAQ:ALMS Alumis Inc. Stock
Home listing (NASDAQ) of Alumis Inc.
Follow Alumis Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ALMS
$6.38 USD -0.35 (-5.2%)
Close on Nov 2, 2026
- Day range
- $6.26 – $6.81 USDNov 2, 2026
- Volume
- 1.43M sharesNov 2, 2026
- Market cap
- $825.8M USDAt the close on Nov 2, 2026 · price × 129.4M shares outstanding
- 52-week range
- $4.39 – $31.35 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $26.86M USDMedian day 1.72M shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALMS · Home | $6.38 USD | -0.35 (-5.2%) | 1,430,090 | $6.81 | $6.81 | $6.255 | $6.73 | Close on Nov 2, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · NASDAQ:ALMS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.38 | -0.35 | -5.2% | $6.81 | $6.81 | $6.255 | 1,430,090 | |
| $6.73 | -0.16 | -2.3% | $6.84 | $6.92 | $6.46 | 2,236,875 | |
| $6.89 | -0.24 | -3.4% | $7.19 | $7.245 | $6.68 | 2,743,111 | |
| $7.13 | +0.49 | +7.4% | $6.60 | $7.18 | $6.59 | 2,431,728 | |
| $6.64 | +0.13 | +2.0% | $6.51 | $6.69 | $6.30 | 3,258,301 | |
| $6.51 | -0.27 | -4.0% | $6.76 | $6.825 | $6.375 | 1,119,816 | |
| $6.78 | -0.04 | -0.6% | $6.68 | $6.82 | $6.48 | 1,230,171 | |
| $6.82 | +0.01 | +0.1% | $6.72 | $6.945 | $6.655 | 1,503,555 | |
| $6.81 | +0.11 | +1.6% | $6.75 | $6.945 | $6.66 | 1,230,135 | |
| $6.70 | +0.36 | +5.7% | $6.33 | $6.725 | $6.25 | 1,534,294 | |
| $6.34 | +0.22 | +3.6% | $6.12 | $6.43 | $6.10 | 1,483,621 | |
| $6.12 | -0.19 | -3.0% | $6.31 | $6.31 | $6.01 | 2,496,575 | |
| $6.31 | +0.25 | +4.1% | $6.11 | $6.50 | $6.08 | 2,786,515 | |
| $6.06 | -0.50 | -7.6% | $6.47 | $6.55 | $6.015 | 2,298,082 | |
| $6.56 | -0.50 | -7.1% | $7.01 | $7.01 | $6.535 | 1,899,400 | |
| $7.06 | -0.10 | -1.4% | $7.13 | $7.31 | $6.97 | 1,601,100 | |
| $7.16 | +0.19 | +2.7% | $7.04 | $7.285 | $6.90 | 1,371,100 | |
| $6.97 | +0.20 | +3.0% | $6.66 | $7.02 | $6.61 | 2,853,100 | |
| $6.77 | -0.16 | -2.3% | $6.82 | $6.95 | $6.71 | 2,167,200 | |
| $6.93 | +0.09 | +1.3% | $6.89 | $6.95 | $6.64 | 1,745,500 | |
| $6.84 | -0.01 | -0.1% | $6.99 | $7.17 | $6.78 | 3,869,200 | |
| $6.85 | -0.36 | -5.0% | $7.28 | $7.31 | $6.635 | 2,624,700 | |
| $7.21 | -0.18 | -2.4% | $7.40 | $7.48 | $7.15 | 2,130,400 | |
| $7.39 | +0.10 | +1.4% | $7.35 | $7.555 | $7.15 | 1,402,000 | |
| $7.29 | +0.13 | +1.8% | $7.16 | $7.41 | $7.13 | 1,667,900 | |
| $7.16 | +0.06 | +0.8% | $7.10 | $7.22 | $6.83 | 2,244,700 | |
| $7.10 | -0.19 | -2.6% | $7.33 | $7.38 | $7.035 | 1,718,100 | |
| $7.29 | -0.15 | -2.0% | $7.43 | $7.45 | $7.22 | 2,604,400 | |
| $7.44 | -0.67 | -8.3% | $8.03 | $8.075 | $7.31 | 2,693,500 | |
| $8.11 | +0.21 | +2.7% | $8.01 | $8.14 | $7.67 | 2,523,100 | |
| $7.90 | +0.13 | +1.7% | $7.82 | $7.92 | $7.56 | 2,431,300 | |
| $7.77 | -0.05 | -0.6% | $7.83 | $7.905 | $7.535 | 6,384,000 | |
| $7.82 | -0.12 | -1.5% | $8.03 | $8.11 | $7.755 | 3,514,800 | |
| $7.94 | -0.46 | -5.5% | $8.45 | $8.47 | $7.79 | 4,800,700 | |
| $8.40 | -0.82 | -8.9% | $9.18 | $9.20 | $8.31 | 4,003,700 | |
| $9.22 | +0.04 | +0.4% | $9.25 | $9.356 | $9.02 | 4,027,100 | |
| $9.18 | -0.72 | -7.3% | $9.99 | $10.11 | $9.14 | 3,434,300 | |
| $9.90 | +0.10 | +1.0% | $10.55 | $10.55 | $9.65 | 4,731,200 | |
| $9.80 | -0.78 | -7.4% | $10.49 | $10.67 | $9.77 | 3,874,800 | |
| $10.58 | -0.52 | -4.7% | $11.05 | $11.22 | $10.25 | 4,490,300 | |
| $11.10 | -0.26 | -2.3% | $11.23 | $11.60 | $11.01 | 3,077,100 | |
| $11.36 | +1.01 | +9.8% | $10.38 | $11.92 | $10.31 | 7,547,600 | |
| $10.35 | +0.88 | +9.3% | $10.16 | $10.77 | $9.95 | 10,377,000 | |
| $9.47 | -12.34 | -56.6% | $9.93 | $11.06 | $8.75 | 28,399,000 | |
| $21.81 | -0.57 | -2.5% | $22.29 | $22.55 | $21.28 | 1,372,900 | |
| $22.38 | -0.83 | -3.6% | $22.83 | $23.28 | $22.35 | 655,000 | |
| $23.21 | -0.41 | -1.7% | $23.49 | $24.13 | $23.08 | 503,600 | |
| $23.62 | -0.34 | -1.4% | $24.14 | $24.14 | $23.16 | 642,500 | |
| $23.96 | +0.93 | +4.0% | $23.52 | $24.04 | $23.24 | 587,300 | |
| $23.03 | -1.14 | -4.7% | $23.69 | $23.74 | $22.43 | 850,600 | |
| $24.17 | +1.31 | +5.7% | $22.98 | $24.70 | $22.21 | 934,200 | |
| $22.86 | -1.13 | -4.7% | $23.76 | $23.93 | $22.03 | 949,300 | |
| $23.99 | -0.89 | -3.6% | $25.48 | $25.94 | $23.84 | 937,800 | |
| $24.88 | -0.62 | -2.4% | $25.26 | $25.32 | $24.36 | 661,700 | |
| $25.50 | +0.19 | +0.8% | $25.05 | $25.71 | $24.90 | 844,000 | |
| $25.31 | +0.90 | +3.7% | $23.19 | $25.38 | $23.13 | 1,217,200 | |
| $24.41 | -1.14 | -4.5% | $25.59 | $25.86 | $24.06 | 832,200 | |
| $25.55 | +0.18 | +0.7% | $25.51 | $26.00 | $24.85 | 991,800 | |
| $25.37 | -2.16 | -7.8% | $27.68 | $27.69 | $23.80 | 1,324,326 | |
| $27.53 | -0.07 | -0.3% | $27.36 | $27.94 | $27.00 | 458,965 | |
| $27.60 | -0.20 | -0.7% | $28.00 | $28.17 | $26.84 | 843,500 | |
| $27.80 | +0.68 | +2.5% | $27.10 | $28.56 | $27.10 | 653,500 | |
| $27.12 | 0.00 | 0.0% | $27.24 | $27.94 | $26.70 | 630,500 | |
| $27.12 | +1.00 | +3.8% | $26.35 | $27.38 | $26.18 | 754,400 | |
| $26.12 | -2.13 | -7.5% | $27.69 | $27.70 | $25.29 | 1,388,000 |
- Ticker
- NASDAQ:ALMS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 9, 2026
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
Latest deck · Sep 1, 2026
Technical Presentation (September 2026)
Technical · 20 slides
Latest news
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
Oct 9, 2026
Closed $7.16 (+2.7%) on Oct 9, 2026
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Aug 14, 2026
Closed $25.31 (+3.7%) on Aug 14, 2026
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
Aug 10, 2026
Closed $25.37 (-7.8%) on Aug 11, 2026
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
May 14, 2026
Closed $24.63 (-0.9%) on May 14, 2026
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Mar 28, 2026
Closed $20.21 (-18.5%) on Mar 30, 2026
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Mar 19, 2026
Closed $25.38 (-0.2%) on Mar 19, 2026
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
Mar 18, 2026
Closed $25.42 (-3.0%) on Mar 18, 2026
Alumis to Present at the Leerink Partners Global Healthcare Conference
Mar 2, 2026
Closed $29.72 (+0.1%) on Mar 2, 2026
Alumis to Participate in Upcoming February Investor Conferences
Feb 5, 2026
Closed $26.34 (0.0%) on Feb 5, 2026
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jan 9, 2026
Closed $21.09 (+7.8%) on Jan 12, 2026
Decks
Technical Presentation (September 2026)
Technical · 20 slides · Sep 1, 2026
Investor Presentation (August 2026)
Investor deck · 37 slides · August 2026
Investor Presentation (June 2026)
Investor deck · 36 slides · Jun 29, 2026
Technical Presentation (May 2026)
Technical · 21 slides · May 14, 2026
Alumis Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 49 in all · newest Oct 9, 2026 · oldest 2024
- Decks
- 18 decks · latest Sep 1, 2026
Where Alumis Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALMS · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ALMS | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Alumis Inc.